|About DHS||Aging||Partners & Providers||Children||Disabilities||Economic Supports||Health Care||Publications||Licensing|
MHCP Enrolled Providers – Pharmacies
Fee-for-Service PA Criteria Sheet – Egrifta
FDA approved indication
Tesamorelin (Egrifta™) is a growth hormone releasing factor (GRF) analog indicated for the reduction of excess abdominal fat* in HIV-infected patients with lipodystrophy.
Tesamorelin is not indicated for weight loss management; it has a weight neutral effect.
*Defined in clinical trials as 105 cm
MHCP Provider Call Center (651) 431-2700 or 1-800-366-5411
Report/Rate this page
|© 2016 Minnesota Department of Human Services Online||Updated: 7/26/11 1:53 PM | Accessibility | Terms/Policy | Contact DHS | Top of Page ||